Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to new research. Apixaban lowers the ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...

VANCOUVER, Feb. 13, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that a poster titled "Medical conversion with Vernakalant on postoperative cardio-surgical ...

Please provide your email address to receive an email when new articles are posted on . Sinus rhythm was restored in an effective, safe and rapid manner using drug-shock or shock-only strategies among ...

A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...

LISBON — After delaying cardioversion based on a "wait-and-see" (WAS) approach for recent onset, symptomatic atrial fibrillation (AF) was just as good as acute cardioversion (AC) in getting patients ...

Pharmacologic cardioversion followed by electrical cardioversion and electrical cardioversion only were found to be safe and effective in patients presenting to the emergency department with recent ...

The drug-shock strategy was more effective for patients experiencing atrial fibrillation for the first time and for patients younger than 70 years, the researchers said. Both the anti-arrhythmia drug ...

VANCOUVER, Cardiome Pharma Corp. today announced that an independent study conducted by investigators at the University of Leipzig Heart Center,Germany, found that intravenous vernakalant facilitated ...

MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin a clinical trial of its ...